Stockscreener 앱 받기
16.76
4.68%
0.75
시간 외 거래:
16.76
전일 마감가:
$16.01
열려 있는:
$15.84
하루 거래량:
439.15K
Relative Volume:
1.33
시가총액:
$361.91M
수익:
-
순이익/손실:
$11.77M
주가수익비율:
28.97
EPS:
0.5785
순현금흐름:
$-19.23M
1주 성능:
+18.95%
1개월 성능:
-2.27%
6개월 성능:
-40.79%
1년 성능:
+8.48%
1일 변동 폭
$15.49
$17.20
1주일 범위
$14.11
$17.20
52주 변동 폭
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
명칭
Tourmaline Bio Inc
전화
646-481-9832
주소
27 WEST 24TH STREET, NEW YORK
TRML을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
16.76 | 361.91M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-15 | 개시 | Jefferies | Buy |
| 2023-12-04 | 재개 | H.C. Wainwright | Buy |
| 2023-11-17 | 개시 | Truist | Buy |
| 2023-10-31 | 개시 | Guggenheim | Buy |
| 2023-10-25 | 개시 | Piper Sandler | Overweight |
| 2022-10-20 | 개시 | H.C. Wainwright | Buy |
| 2022-07-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
모두보기
Tourmaline Bio Inc 주식(TRML)의 최신 뉴스
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - ADVFN
Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation - Yahoo Finance
Vanguard Group Inc. Boosts Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Equity LifeStyle Properties, Inc. (NYSE:ELS) Position Boosted by Wellington Management Group LLP - Defense World
Wellington Management Group LLP Buys Shares of 114,300 Vodafone Group Public Limited (NASDAQ:VOD) - Defense World
Wellington Management Group LLP Buys 8,001 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Increased by Wellington Management Group LLP - Defense World
Wellington Management Group LLP Acquires 813 Shares of Ferrovial SE (NASDAQ:FER) - Defense World
Corebridge Financial Inc. Trims Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Wellington Management Group LLP Raises Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Corebridge Financial Inc. Has $199,000 Holdings in Red Violet, Inc. (NASDAQ:RDVT) - Defense World
KLP Kapitalforvaltning AS Invests $47,000 in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Corebridge Financial Inc. Lowers Position in Chatham Lodging Trust (NYSE:CLDT) - Defense World
Franklin Resources Inc. Sells 5,012 Shares of Genworth Financial, Inc. (NYSE:GNW) - Defense World
7,700 Shares in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Acquired by KLP Kapitalforvaltning AS - Defense World
Corebridge Financial Inc. Has $213,000 Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Corebridge Financial Inc. Sells 557 Shares of Net Lease Office Properties (NYSE:NLOP) - Defense World
Arrowstreet Capital Limited Partnership Decreases Stake in Alexander & Baldwin, Inc. (NYSE:ALEX) - Defense World
Arhaus, Inc. (NASDAQ:ARHS) Shares Bought by Vanguard Group Inc. - Defense World
American Century Companies Inc. Invests $474,000 in CARGO Therapeutics, Inc. (NASDAQ:CRGX) - Defense World
Can TRANQUILITY Data Propel Tourmaline Bio's Stock Price? - RTTNews
Truist Cuts Price Target on Tourmaline Bio to $63 From $74, Keeps Buy Rating - marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of “Buy” by Brokerages - Defense World
Talaris Therapeutics stock hits 52-week low at $11.85 By Investing.com - Investing.com Canada
Prudential Financial Inc. Cuts Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data - Seeking Alpha
Should You Invest in H&R Block Inc (HRB) Now? - News Heater
Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leading Factor Driving the Thyroid Eye Disease (TED) Market in 2025: Thyroid Disorders And Their Influence ... - WhaTech
ProfittoPath - TradingView
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Sold by AlphaQuest LLC - Defense World
Tourmaline Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, Wedbush Analyst Says - Defense World
HC Wainwright Raises Tourmaline Bio (NASDAQ:TRML) Price Target to $50.00 - Defense World
H.C. Wainwright raises Tourmaline Bio stock target to $50 By Investing.com - Investing.com Canada
Tourmaline Bio price target raised to $43 from $42 at Wedbush - TipRanks
H.C. Wainwright raises Tourmaline Bio stock target to $50 - Investing.com India
Wedbush Lifts Price Target on Tourmaline Bio to $43 From $42, Keeps Outperform Rating - Marketscreener.com
Novo Nordisk (0QIU) Gets a Buy from UBS - The Globe and Mail
Tourmaline Bio’s 2024 Financial Results and Strategic Advances - TipRanks
Tourmaline Bio shares fall as Q4 loss widens - Investing.com
Tourmaline Bio shares fall as Q4 loss widens By Investing.com - Investing.com UK
TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings - Nasdaq
Tourmaline Bio, Inc. SEC 10-K Report - TradingView
Tourmaline Bio's cash position to provide cash runway into second half of 2027 -March 13, 2025 at 07:39 am EDT - Marketscreener.com
Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook - Nasdaq
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials - StockTitan
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday - Defense World
Tourmaline Bio Inc (TRML) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):